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Introduction 
 Complete androgen insensitivity syndrome (CAIS), or Morris’ syndrome, is an X-linked 
recessive disorder of sex development, in which affected individuals are phenotypically female but 
have an XY karyotype and testes, with an estimated prevalence between 1:20400 and 1:99100 
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among genetic males [1]. Patients present with female external genitalia, short blind ended vagina, 
absent uterus, normal breast development, but scant pubic and axillary hair. 
 Cushing’s Syndrome (CS) is a clinical state related to hypercortisolaemia. In women, it 
may present with menstrual cycle disturbances, mainly oligo- or amenorrhoea. Additionally, 
overproduction of adrenal androgens leads to hirsutism, acne, and infertility [2], which will not be 
noticed in CAIS patients, leading to diagnostic difficulties. 
 The aim of this report is to present the specificity of the clinical picture of CS, developed 
in a patient with CAIS. 
 
Case report 
 Our patient, at three months of age, was diagnosed due to bilateral inguinal tumours (right 
26 × 13 mm, left 25 × 15 mm, on MRI), which, following removal, were confirmed to be testes. A 
hypoplastic vagina, together with lack of uterus and ovaries, were demonstrated. Hormonal 
evaluation revealed markedly elevated testosterone, follitropin (FSH), and luteinising hormone 
(LH) serum concentrations. Genetic test revealed a 46 XY karyotype. The patient was brought up 
as a girl. During pubertal period, oestrogen therapy was introduced, resulting in the development 
of a full female phenotype. 
 At the age of 27 years the patient presented with central fat tissue accumulation, 
supraclavicular pads, and slimming of limbs. She also reported muscle weakness and a weight 
increase of 8 kg in three years. The results of laboratory tests were suggestive of ACTH-dependent 
hypercortisolaemia (Tab. I). In addition, very high gonadotropin concentrations were detected, 
accompanied by low oestradiol and normal testosterone levels. Other biochemical tests revealed a 
slight TSH suppression combined with low free triiodothyronine (fT3) concentration, which might 
also reflect hypercortisolaemia. On densitometry osteoporosis of the lumbar spine (T-score minus 
2.8), osteopaenia in the femur neck (T-score minus 1.8) was detected. MRI demonstrated a pituitary 
microadenoma (Fig. 1). She underwent transsphenoidal surgery. Histopathological examination 
confirmed the diagnosis of an ACTH-secreting pituitary adenoma. The patient achieved complete 
biochemical remission, with no evidence of hypopituitarism. Postoperative MRI demonstrated no 
signs of recurrence (Fig. 2). A sustained remission of the disease was observed on 12-month 
follow-up visit. 
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Discussion 
 Our report summarises distinct clinical manifestation of hypercortisolaemia in the first 
patient with CAIS to suffer from CS reported in the world literature. One of the presentations of 
CAIS is either inguinal swellings or hernias being male testes during infancy, similarly to our 
patient. However, CAIS patients may remain undiagnosed until primary amenorrhoea occurs [3]. 
Female adolescents with CAIS develop breasts and have a pubertal growth spurt at an appropriate 
age, but no menses. Development of oestrogen-dependent secondary sexual characteristics occurs 
as a result of excessive aromatisation of androgens. Pubic and axillary hair is usually absent or 
scarce [4]. 
 Patients with CAIS require careful oncological vigilance because the risk of gonadal tumour 
is 0.8–22%. Our patient underwent gonadectomy at infancy, but currently more authors 
recommend deferring removal of the gonads until after the completion of puberty. Patients require 
oestrogen replacement therapy from puberty to develop and preserve secondary sexual 
characteristics as well as maintain bone mass. Monitoring of bone mineral density in these patients 
is advised. Our patient presented with decreased bone mass, more pronounced in the lumbar spine 
than in the femur neck, which might be suggestive of the additional influence of 
hypercortisolaemia. 
 In patients with CAIS the diagnosis of CS can be difficult. Menstrual disturbances or 
infertility might be one of the first clinical manifestations of CS but could be not suggestive in 
patients with CAIS. Additionally, oestrogen therapy may lead to an increase of cortisol-binding 
globulin (CBG) and cause an increase in total cortisol concentration. Elevated cortisol due to CS 
might be erroneously interpreted as a result of oestrogen therapy and thus neglected. Therefore, the 
CS diagnosis should be primarily based on disturbed diurnal rhythm of cortisol secretion, 
accompanied by normal or increased ACTH and lack of cortisol suppression during dexamethasone 
test. In these patients, assessment of free serum cortisol, cortisol in saliva or 24-h urinary cortisol 
excretion might be more useful. 
 In conclusion, the complexity of the diagnostics of CS in the presence of CAIS rest upon 
the fact that some classic presentations of hypercortisolaemia (menstrual irregularities, virilisation, 
infertility) present lower diagnostic value. Moreover, biochemical diagnostics might also be 
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challenging. Inadequate hormonal replacement therapy and lack of the positive influence of 
androgens may further exacerbate the adverse effect of hypercortisolaemia on bone mineral 
density. 
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Table I. Results of biochemical tests on diagnosis of ACTH-dependent Cushing’s syndrome and 
following successful neurosurgical procedure (the patient had withdrawn oestrogen 
supplementation two months prior to admission) 
Parameter Before 
surgery 
2 days 
following 
surgery 
Follow-up 12 
months following 
surgery 
Reference 
range 
Serum cortisol [nmol/L] 8 
AM 
657 
989 
11 383 274–527 
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497 (during CRH-
stimulation test) 
Serum cortisol [nmol/L] 6 
PM 
524 – 95  
Serum cortisol [nmol/L] 11 
PM 
389 – 18 < 50 
Serum ACTH [pg/mL] 73.61 2.63 28.77 
 
7.20–63.30 
Serum DHEA-S [µg/dL] 603 21  38 99–340 
Urinary free cortisol [12-
486] nmol/24 h 
346 
298 
– –  
Serum cortisol [nmol/L] 8 
AM following 1 mg 
dexamethasone test 
324 – – < 50 
FSH [mlU/mL] 110.2 29.1 63.2 2.4–12.5 
LH [mlU/ml] 79.2 7.4 48.7 3.5–12.5 
Oestradiol [pg/ml] 9 – < 5  
Testosterone [nmol/L] 2.3 – < 0.1 0.2–2.9 
Prolactin [µIU/ml] 406 727 364 70–510 
Post-PEG prolactin – 82% –  
TSH [µIU/ml] 0.99 3.03 3.91 0.27–4.20 
fT3 [pmol/l] 3.59 6.08 5.94 3.90–6.70 
fT4 [pmol/l] 15.64 17.96 17.59 11.5–21.0 
Fasting insulin [µU/ml] 16.04 – 10.81 3–17 
 
Fasting glucose 79# 83* 87  
ACTH — adrenocorticotropin; CRH — corticotropin releasing hormone; DHEA-S — 
dehydroepiandrosterone sulphate; FSH — follitropin; fT3 — free triiodothyronine; fT4 — free 
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thyroxine; LH — luteinising hormone; PEG — polyethylene glycol; TSH — thyrotropin; #during 
metformin treatment 1 g/d; *without metformin treatment  
 
Figure 1. Pituitary gland before surgical treatment. Microadenoma on the right side of inferior part 
of anterior lobe (width 4 mm, height 2.5 mm). A. Coronal T1-weighted image after contrast media 
administration. Hypointense region represents microadenoma (arrow). B. Sagittal T1-weighted 
image after contrast media administration. Hypointense region represents microadenoma (arrow) 
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Figure 2. Pituitary gland in the same patient after surgical treatment. Complete resection of 
microadenoma. No visible hypointense regions corresponding to microadenoma. A. Coronal T1-
weighted image after contrast media administration. B. Sagittal T1-weighted image after contrast 
media administration 
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